Johnson & JohnsonvsPacira BioSciences

JNJ and PCRX stock compared: price, dividend, valuation and results, from SEC filings.

PCRX

Pacira BioSciences, Inc.

$36.48

Value $1.5B

+0.00%
PCRX's page

Johnson & Johnson (JNJ) has a market value of $652B and Pacira BioSciences (PCRX) $1.5B. Over the last year, with dividends, JNJ moved +45.4% and PCRX +53.4%. The P/E is 40.5 for JNJ and 39.2 for PCRX. Dividend yield: JNJ 1.95%, PCRX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$652B

    PCRX$1.5B

    JNJ is 441 times PCRX

  • Revenue, 12 months

    JNJ$99.3B

    PCRX$743M

    JNJ is 134 times PCRX

  • Net income, 12 months

    JNJ$16.1B

    PCRX$38M

    JNJ is 427 times PCRX

  • Operating margin

    JNJ–

    PCRX4.8%

  • ROIC

    JNJ12.4%

    PCRX2.4%

    10.0 points apart

  • P/E

    JNJ40.5

    PCRX39.2

    About the same

  • Dividend yield

    JNJ2.0%

    PCRX0.0%

    2.0 points apart

  • 5-year return

    JNJ+97.0%

    PCRX-36.0%

    133.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+97.0%

PCRX-36.0%

5010015020020222023202420252026
Returns by period
PeriodJNJWith dividendsPCRXWith dividends
1 year since November 14, 2025+45.4%Price +42.2%+53.4%Price +53.4%
3 years since November 17, 2023+102.6%+26.5% a yearPrice +86.1%+30.8%+9.4% a yearPrice +30.8%
5 years since November 16, 2021+97.0%+14.5% a yearPrice +71.3%-36.0%-8.5% a yearPrice -36.0%
10 years since November 21, 2016+215.8%+12.2% a yearPrice +142.3%+4.1%+0.4% a yearPrice +4.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonPCRXPacira BioSciences

Valuation

JNJPCRX
Valuation
Price$270.47$36.48
Market value$652B$1.5B
Enterprise value (EV)$679B$1.5B
P/E40.539.2
P/E, 5-year median21.9–
P/B8.02.1
EV/EBIT38.341.2
Free cash flow yield3.2%11.4%

Results and growth

JNJPCRX
Results and growth
Revenue, 12 months$99.3B$743M
Net income, 12 months$16.1B$38M
Free cash flow, 12 months$20.6B$169M
Earnings per share, 12 months$6.59$0.93
Revenue growth, year on year6.1%3.6%
Revenue growth a year, past+2.7%over 5 years+11.1%over 5 years
EPS growth a year, past+14.9%over 5 years-45.5%over 5 years

Margins and returns on capital

JNJPCRX
Margins and returns on capital
Gross margin67.6%78.7%
Operating margin–4.8%
Net margin16.2%5.1%
ROIC12.4%2.4%
ROE19.7%5.5%

Balance sheet

JNJPCRX
Balance sheet
Cash$17.2B$296M
Total debt$44.7B$340M
Net debt / EBITDA1.1-0.0
Interest cover18.0×2.5×

Dividends and buybacks

JNJPCRX
Dividends and buybacks
Dividend yield2.0%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%10.0%
Shareholder yield2.9%10.0%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or PCRX

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Pacira BioSciences?

By market value, Johnson & Johnson ($652B) is about 441.3 times Pacira BioSciences ($1.5B), at today's prices.

How did JNJ and PCRX stock do over the last 10 years?

Since November 21, 2016, JNJ's price moved +142.3% and PCRX's +4.1%. With dividends: JNJ +215.8% (+12.2% a year), PCRX +4.1% (+0.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, JNJ or PCRX?

The dividend yield at today's price is 1.95% for Johnson & Johnson and none for Pacira BioSciences. Over the last twelve months they paid $5.28 and – per share.

What is the P/E of JNJ and PCRX?

At today's price, the P/E is 40.5 for JNJ and 39.2 for PCRX. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Johnson & Johnson or Pacira BioSciences?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and 5.1% for Pacira BioSciences, and the operating margin – and 4.8%. Revenue was $99.3B and $743M.

Which is the better investment, Johnson & Johnson or Pacira BioSciences?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.